Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
Alexandre Bazinet(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Debra Bull-Linderman(The University of Texas MD Anderson Cancer Center), Fadi Haddad(Trinity Health), Kelly S. Chien, Koji Sasaki(The University of Texas MD Anderson Cancer Center), Álex Bataller(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Jo Ishizawa(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Abhishek Maiti(The University of Texas MD Anderson Cancer Center), Lucia Masárová(The University of Texas MD Anderson Cancer Center), Danielle Hammond(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Maro Ohanian(The University of Texas MD Anderson Cancer Center)
Cited by 4
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k